Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 1.000
0.00 (0.00%)
Aug 5, 2025, 10:59 AM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$490,982
Profits / Employee
-$5,740,265
Market Cap
43.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 35,686 |
| Danel (Adir Yeoshua) | 4,290 |
| Kamada | 420 |
| Bait Bakfar | 227 |
| SofWave Medical | 126 |
| BrainsWay | 120 |
| Novolog (Pharm-Up 1966) | 936 |
| Ilex Medical | 178 |
Can-Fite BioPharma News
- 8 days ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 8 days ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 12 days ago - Can-Fite BioPharma launches best-efforts offering of ADSs and warrants - Seeking Alpha
- 3 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 4 months ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M - Seeking Alpha
- 4 months ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 4 months ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire